• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Masimo Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    5/6/25 4:14:03 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email
    false 0000937556 0000937556 2025-05-06 2025-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 6, 2025

     

    MASIMO CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33642   33-0368882
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    52 Discovery
    Irvine, CA
    92618

    (Address of principal executive offices, including zip code)

     

    (949) 297-7000

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b))
      ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol   Name of each exchange on which registered
    Common Stock, $0.001 par value   MASI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01Entry into a Material Definitive Agreement.

     

    On May 6, 2025, Masimo Corporation (the “Company”) entered into a definitive Stock Purchase Agreement (the “Agreement”) with Harman International Industries, Incorporated, a Delaware corporation (“Buyer”), pursuant to which the Company has agreed to sell and transfer to Buyer all of the Company’s equity interests in Viper Holdings Corporation, a Delaware corporation (together with its subsidiaries, “Sound United”), which owns and operates the Company’s consumer audio business, for an aggregate purchase price of $350,000,000 in cash, subject to certain adjustments (the “Transaction”).

     

    The Agreement contains representations, warranties and covenants that are customary for a transaction of this type, including, among others, covenants by the Company to conduct the Sound United business in the ordinary course between execution of the Agreement and closing of the Transaction (the “Closing”). The Transaction is subject to the satisfaction of customary closing conditions, including, among other things, (i) the absence of any law or order enjoining or otherwise prohibiting the Transaction, (ii) the receipt of certain regulatory approvals, (iii) the accuracy of the representations and warranties of the parties to the Agreement, subject to certain materiality standards, and (iv) compliance of each party to the Agreement with its covenants in the Agreement in all material respects. Subject to the satisfaction or waiver of certain conditions and the other terms and conditions of the Agreement, the Transaction is expected to close by the end of 2025.

     

    The Agreement contains customary termination rights, including if the Closing has not occurred on or prior to February 6, 2026, subject to potential extensions up to August 6, 2026 in the event the only condition to Closing that remains unsatisfied as of such date is the receipt of certain regulatory approvals and certain other exceptions.

     

    The above description of the Agreement has been included to provide investors with information regarding the terms of the Agreement. It is not intended to provide any other factual information about the Company, Buyer, Sound United or their respective subsidiaries or affiliates.

     

    The foregoing description of the Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Agreement, which the Company intends to file as an exhibit to an amendment to this Current Report on Form 8-K on or about May 7, 2025.

     

    Item 7.01.Regulation FD Disclosure.

     

    On May 6, 2025, the Company published a press release announcing the entry into the Agreement. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    The information in this Item 7.01 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except in the event that the Company expressly states that such information is to be considered filed under the Exchange Act or incorporates it by specific reference in such filing.

     

     

     

     

    Forward Looking Statements

     

    This Current Report on Form 8-K includes forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting the Company, including expectations regarding the timing and completion of the proposed Transaction. These forward-looking statements are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond the Company’s control and could cause its actual results to differ materially and adversely from those expressed in the Company’s forward-looking statements as a result of various risk factors, including, for example: (i) the inability to obtain, or delays in obtaining, any required regulatory or other approvals for the Transaction, or failure to consummate or delay in consummating the Transaction for any other reasons; (ii) the risk that a condition to closing of the Transaction may not be satisfied; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the Agreement; (iv) the outcome of any legal proceedings that may be instituted following announcement of the Transaction; (v) potential unfavorable reactions to the Transaction by customers, competitors, suppliers, employees and Company stockholders; and (vi) each party’s ability to satisfy its respective obligations under the Agreement and any ancillary agreements entered into in connection with the Transaction. You should exercise caution in interpreting and relying on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and could materially affect actual results, performance or achievements. Although the Company believes that the expectations reflected in its forward looking statements are reasonable, it does not know whether its expectations will prove correct. The information contained in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including under the caption “Risk Factors” in the Company’s periodic reports or incorporated therein, identifies other important factors that could result in differences from the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) The following items are filed as exhibits to the Current Report on Form 8-K.

     

    Exhibit
    No.
      Description of Exhibits
    99.1   Press Release, dated May 6, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    Signature

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Masimo Corporation has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      MASIMO CORPORATION
    (Registrant)
         
      By: /s/ Micah Young
      Name: Micah Young
    Executive Vice President & Chief Financial Officer
      Title: (Principal Financial Officer)

     

    Date: May 6, 2025

     

     

    Get the next $MASI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    11/8/2023Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

      American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

      7/8/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

      EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure Masimo (NASDAQ:MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation

      6/10/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Present in the Jefferies Global Healthcare Conference

      Masimo (NASDAQ:MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 1:25 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bower

      5/27/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    SEC Filings

    See more
    • SEC Form 11-K filed by Masimo Corporation

      11-K - MASIMO CORP (0000937556) (Filer)

      6/25/25 6:45:01 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - MASIMO CORP (0000937556) (Filer)

      6/12/25 4:17:11 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by Masimo Corporation

      SD - MASIMO CORP (0000937556) (Filer)

      5/27/25 5:27:13 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Muhsin Bilal exercised 10,000 shares at a strike of $34.51 and sold $1,632,781 worth of shares (10,000 units at $163.28) (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/14/25 5:32:56 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Solomon Darlene J. S. converted options into 1,790 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:55:57 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Scannell Timothy J converted options into 1,383 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:54:23 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    See more
    • Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

      American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

      7/8/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      9/25/24 4:01:23 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      8/30/24 4:56:53 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      7/17/24 5:29:36 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Financials

    Live finance-specific insights

    See more
    • Masimo Reports First Quarter 2025 Results

      Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $372 million, representing 10% on a reported basis; Non-GAAP revenue of $371 million, representing 10% on a constant currency basis(3); GAAP net income per diluted of $0.86; and Non-GAAP net income per diluted share(3) of $1.36, which grew 56% versus prior year period. First Quarter 2025 Results From Discontinued Operations(2): GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer busi

      5/6/25 4:10:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6

      Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participant

      4/24/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Updated Full-Year 2025 Guidance

      Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance. Fourth Quarter 2024 Financial Results: Consolidated revenue was $601 million, representing 9% growth on a reported and constant currency basis(1); Healthcare revenue was $368 million, representing 8% growth on a reported basis and 9% growth on a constant currency basis(1); Non-healthcare revenue was $232 million, representing 11% growth on a reported and constant currency basis(1); GAAP net loss per basic share was ($6.52), which included an impairment of goodwill and intangibles for Sound United

      2/25/25 4:05:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on Masimo with a new price target

      Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

      12/27/24 7:29:29 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Raymond James with a new price target

      Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00

      11/6/24 7:17:22 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously

      6/3/24 7:31:43 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care